Development of neuropeptide drugs that cross the blood-brain barrier

No abstract is available for this paper.

• Publication year

  2011

• Venue

  NeuroRx

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1602/neurorx.2.1.44PMID 15717056PMCID PMC539319
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Post-Occlusion Treatment with BDNF Reduces Infarct Size in a Model of Permanent Occlusion of the Middle Cerebral Artery in Rat

  2004cited by this paper
• Epilepsy, CNS viral injury and dynorphin.

  2004cited by this paper
• Substance P: structure, function, and therapeutics.

  2004cited by this paper
• Brain metastases in melanoma: roles of neurotrophins.

  2004cited by this paper
• Corticotropin‐releasing hormone (CRH) in psychiatry: from stress to psychopathology

  2004cited by this paper
• New trends in the development of opioid peptide analogues as advanced remedies for pain relief.

  2004cited by this paper
• Energy homeostasis, obesity and eating disorders: recent advances in endocrinology.

  2004cited by this paper
• Variable modulation of opioid brain uptake by P-glycoprotein in mice.

  2004cited by this paper
• Leptin signaling in the central nervous system and the periphery.

  2004cited by this paper
• Antinociceptive Structure-Activity Studies with Enkephalin-Based Opioid Glycopeptides

  2004cited by this paper
• Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression.

  2004cited by this paper
• Neurotrophin Effects on Neuroblastoma Cells: Correlation with Trk and p75NTR Expression and Influence of Trk Receptor Bodies

  2004cited by this paper
• Glycopeptide-membrane interactions: glycosyl enkephalin analogues adopt turn conformations by NMR and CD in amphipathic media.

  2003cited by this paper
• Stress responsive neurohormones in depression and anxiety.

  2003cited by this paper
• On the Role of Somatostatin in Seizure Control: Clues from the Hippocampus

  2003cited by this paper
• Neurotrophin secretory pathways and synaptic plasticity.

  2003cited by this paper
• Functional development of neurokinin peptides substance P and neurokinin A in nociception

  2003cited by this paper
• Brain-derived neurotrophic factor, behavior, and new directions for the treatment of mental disorders.

  2003cited by this paper
• CYP1A1 and CYP1B1 in blood-brain interfaces: CYP1A1-dependent bioactivation of 7,12-dimethylbenz(a)anthracene in endothelial cells.

  2003cited by this paper
• Enhancement of therapeutic protein in vivo activities through glycoengineering

  2003cited by this paper
• Lipo α-Amino-β-hydroxy Acids and O-Linked Glycosides: Building Blocks for Ceramyl and Glycosphingoyl Peptides.

  2002cited by this paper
• A new multidrug resistance protein at the blood-brain barrier.

  2002cited by this paper
• Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector.

  2002cited by this paper
• Crystal structure of biphalin sulfate: a multireceptor opioid peptide.

  2002cited by this paper
• Pharmacokinetics and Brain Uptake of Biotinylated Basic Fibroblast Growth Factor Conjugated to a Blood-Brain Barrier Drug Delivery System

  2002cited by this paper
• Clinical potentials of neuropeptide Y family of hormones.

  2002cited by this paper
• Localisation of breast cancer resistance protein in microvessel endothelium of human brain

  2002cited by this paper
• Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs

  2001cited by this paper
• Improved blood-brain barrier penetration and enhanced analgesia of an opioid peptide by glycosylation.

  2001cited by this paper
• Functional relevance of carnitine transporter OCTN2 to brain distribution of l‐carnitine and acetyl‐l‐carnitine across the blood–brain barrier

  2001cited by this paper
• Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin.

  2001cited by this paper
• Lipo alpha-amino-beta-hydroxy acids and O-linked glycosides: building blocks for ceramyl and glycosphingoyl peptides.

  2001cited by this paper
• Receptor-Mediated Gene Targeting to Tissues In Vivo Following Intravenous Administration of Pegylated Immunoliposomes

  2001cited by this paper
• Brain-specific expression of an exogenous gene after i.v. administration

  2001cited by this paper
• Molecular physiology and pathophysiology of tight junctions in the blood–brain barrier

  2001cited by this paper
• Neuroprotection in Transient Focal Brain Ischemia After Delayed Intravenous Administration of Brain-Derived Neurotrophic Factor Conjugated to a Blood-Brain Barrier Drug Targeting System

  2001cited by this paper
• Pharmacodynamic and pharmacokinetic characterization of poly(ethylene glycol) conjugation to met-enkephalin analog [D-Pen2, D-Pen5]-enkephalin (DPDPE).

  2001influential reference
• Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide.

  2000cited by this paper
• Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier.

  2000cited by this paper
• Enkephalin-based drug design: conformational analysis of O-linked glycopeptides by NMR and molecular modeling

  2000cited by this paper
• Assessment of Stereoselectivity of Trimethylphenylalanine Analogues of δ‐Opioid [D‐Pen2,D‐Pen5]‐Enkephalin

  2000influential reference
• Implications of species difference for clinical investigation: studies on the renin-angiotensin system.

  2000cited by this paper
• Improved bioavailability to the brain of glycosylated Met-enkephalin analogs.

  2000cited by this paper
• Noninvasive gene targeting to the brain.

  2000cited by this paper
• Ischemic Brain Damage in Mice after Selectively Modifying BDNF or NT4 Gene Expression

  2000cited by this paper
• N-terminally modified glucagon-like peptide-1(7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo.

  2000cited by this paper
• Assessment of stereoselectivity of trimethylphenylalanine analogues of delta-opioid [D-Pen(2),D-Pen(5)]-enkephalin.

  2000cited by this paper
• Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability.

  2000influential reference
• Controlled-Release, Pegylation, Liposomal Formulations: New Mechanisms in the Delivery of Injectable Drugs

  2000cited by this paper
• Specific renal delivery of sugar-modified low-molecular-weight peptides.

  1999cited by this paper
• The effect of conformation of the acyloxyalkoxy-based cyclic prodrugs of opioid peptides on their membrane permeability.

  1999cited by this paper
• Neuroprotection mediated via neurotrophic factors and induction of neurotrophic factors.

  1999cited by this paper
• Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker.

  1999cited by this paper
• Localization of the Organic Anion Transporting Polypeptide 2 (Oatp2) in Capillary Endothelium and Choroid Plexus Epithelium of Rat Brain

  1999cited by this paper
• Neuroprotection with noninvasive neurotrophin delivery to the brain.

  1999cited by this paper
• Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients.

  1999cited by this paper
• The effect of halogenation on blood-brain barrier permeability of a novel peptide drug.

  1999cited by this paper
• A comparison of blood-brain barrier and blood-nerve barrier endothelial cell markers

  1999cited by this paper
• Renal drug targeting using a vector "alkylglycoside".

  1999cited by this paper
• Molecular Cloning and Characterization of a New Multispecific Organic Anion Transporter from Rat Brain*

  1999cited by this paper
• NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity.

  1999cited by this paper
• Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier.

  1999cited by this paper
• In vivo metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506) in rats and dogs: pharmacokinetics, isolation, identification, and quantification of metabolites.

  1999cited by this paper
• Renal targeting of arginine-vasopressin by modification with carbohydrates at the tyrosine side chain.

  1999cited by this paper
• Octanol–water partition of nonzwitterionic peptides: Predictive power of a molecular size‐based model

  1998cited by this paper
• Multidrug Resistance‐Related Transport Proteins in Isolated Human Brain Microvessels and in Cells Cultured from These Isolates

  1998cited by this paper
• Altered disposition and antinociception of [D-penicillamine(2,5)] enkephalin in mdr1a-gene-deficient mice.

  1998cited by this paper
• Glycodermorphins: opioid peptides with potent and prolonged analgesic activity and enhanced blood‐brain barrier penetration

  1998cited by this paper
• Octanol-water partition: searching for predictive models.

  1998cited by this paper
• Blood-brain barrier permeability and bioavailability of a highly potent and mu-selective opioid receptor antagonist, CTAP: comparison with morphine.

  1997cited by this paper
• Alkaline phosphatase expression in cultured endothelial cells of aorta and brain microvessels: induction by interleukin-6-type cytokines and suppression by transforming growth factor betas.

  1997cited by this paper
• Structure-internalization relationship for adsorptive-mediated endocytosis of basic peptides at the blood-brain barrier.

  1997cited by this paper
• The entry of [D-penicillamine2,5]enkephalin into the central nervous system: saturation kinetics and specificity.

  1997cited by this paper
• Brain and Spinal Cord Distribution of Biphalin: Correlation with Opioid Receptor Density and Mechanism of CNS Entry

  1997cited by this paper
• Extensive Biliary Excretion of the Model Opioid Peptide [D-PEN2,5] Enkephalin in Rats

  1997cited by this paper
• Post-occlusion treatment with BDNF reduces infarct size in a model of permanent occlusion of the middle cerebral artery in rat

  1997cited by this paper
• HIV-1 protein gp120 crosses the blood-brain barrier: role of adsorptive endocytosis.

  1997cited by this paper
• THE EFFECT OF GLYCOSYLATION ON THE UPTAKE OF AN ENKEPHALIN ANALOGUE INTO THE CENTRAL NERVOUS SYSTEM

  1996cited by this paper
• Enkephalin analog prodrugs: assessment of in vitro conversion, enzyme cleavage characterization and blood-brain barrier permeability.

  1996cited by this paper
• Passage of a δ‐Opioid Receptor Selective Enkephalin, [d‐Penicillamine2,5]Enkephalin, Across the Blood‐Brain and the Blood‐Cerebrospinal Fluid Barriers

  1996cited by this paper
• Serum interspecies differences in metabolic pathways of bradykinin and [des-Arg9]BK: influence of enalaprilat.

  1996cited by this paper
• Angiotensin II stimulates T-type Ca2+ channel currents via activation of a G protein, Gi.

  1996cited by this paper
• Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system.

  1996cited by this paper
• Localization of Purine Metabolizing Enzymes in Bovine Brain Microvessel Endothelial Cells: An Enzymatic Blood-Brain Barrier for Dideoxynucleosides?

  1996cited by this paper
• Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles).

  1995cited by this paper
• Hydrogen Bonding Potential as a Determinant of the in Vitro and in Situ Blood–Brain Barrier Permeability of Peptides

  1994cited by this paper
• Structural and functional aspects

  1994cited by this paper
• Glycation increases the permeability of proteins across the blood-nerve and blood-brain barriers.

  1994cited by this paper
• Localization of Drug‐Metabolizing Enzyme Activities to Blood‐Brain Interfaces and Circumventricular Organs

  1994cited by this paper
• Transport of Human Recombinant Brain-Derived Neurotrophic Factor (BDNF) Through the Rat Blood−Brain Barrier in Vivo Using Vector-Mediated Peptide Drug Delivery

  1994cited by this paper
• Effect of peptidases at the blood brain barrier on the permeability of enkephalin.

  1994cited by this paper
• Complete inactivation of target mRNA by biotinylated antisense oligodeoxynucleotide-avidin conjugates.

  1994cited by this paper
• Enzymatic barrier protects brain capillaries from leukotriene C4.

  1994cited by this paper
• Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier.

  1994influential reference
• Localization of immunoreactive glutamyl aminopeptidase in rat brain. I. Association with cerebral microvessels.

  1993cited by this paper
• Time course, localization and pharmacological modulation of immediate early inducible genes, brain-derived neurotrophic factor and trkB messenger RNAs in the rat brain following photochemical stroke.

  1993cited by this paper
• Protein glycosylation. Structural and functional aspects.

  1993cited by this paper
• Antinociceptive activity of liposome-entrapped calcitonin by systemic administration in mice.

  1993cited by this paper
• Blood-brain barrier penetration and in vivo activity of an NGF conjugate.

  1993cited by this paper
• Delivery of peptides and proteins through the blood-brain barrier.

  1993cited by this paper

• Bioconjugates for improved delivery of oligonucleotide therapeutics to the central nervous system.

  2026cites this paper
• Modulating neuropeptide Y pathways to combat nicotine addiction through emerging evidence and future directions.

  2025cites this paper
• Engineered RVG29-Conjugated Chitosan for Enhanced Brain Delivery of Kisspeptin Agonists and Antagonists in Reproductive Health

  2025cites this paper
• Modulation of neuropathological pathways by bioactive peptides and proteins/polypeptides: Targeting oxidative stress in neurodegenerative diseases.

  2025cites this paper
• Targeting Acid-Sensing Ion Channels with Toxin Peptides: Analgesic Mechanisms and Biosynthesis Development

  2025cites this paper
• Unnatural Amino Acids: Strategies, Designs, and Applications in Medicinal Chemistry and Drug Discovery.

  2024cites this paper
• Research progress on intranasal treatment for Parkinson's disease

  2024influential citation
• Unveiling the Mysteries of the Blood-Brain Barrier: The Problem of the Brain/spinal Pharmacotherapy.

  2024cites this paper
• Genetic-epigenetic-neuropeptide associations in mood and anxiety disorders: Toward personalized medicine.

  2024cites this paper
• A novel delta opioid receptor specific peptide reduces craving in an animal model of cocaine seeking

  2024cites this paper
• Recent Uses of Lipid Nanoparticles, Cell-Penetrating and Bioactive Peptides for the Development of Brain-Targeted Nanomedicines against Neurodegenerative Disorders

  2023cites this paper
• Intranasal delivery of mitochondrial protein humanin rescues cell death and promotes mitochondrial function in Parkinson's disease

  2023influential citation
• Characterization of isomeric acetyl amino acids and di-acetyl amino acids by LC/MS/MS.

  2023cites this paper
• Overcoming the shortcomings of peptide-based therapeutics

  2022cites this paper
• Theoretical and Applied Concepts of Nanocarriers for the Treatment of Parkinson's Diseases

  2022cites this paper
• Impact of Early Intravenous Haemostatic Drugs on Brain Haemorrhage Patients and Their Image Segmentation Based on RGB-D Images

  2022cites this paper
• Current Strategies to Enhance Delivery of Drugs across the Blood–Brain Barrier

  2022cites this paper
• Oxytocin Dynamics in the Body and Brain Regulated by the Receptor for Advanced Glycation End-Products, CD38, CD157, and Nicotinamide Riboside

  2022cites this paper
• Functionalization of Morin-Loaded PLGA Nanoparticles with Phenylalanine Dipeptide Targeting the Brain

  2022cites this paper
• Endogenous Opioid Levels Do Not Correlate With Itch Intensity and Therapeutic Interventions in Hepatic Pruritus

  2021cites this paper
• Utilisation of compounds from venoms in drug discovery.

  2021cites this paper
• Blood-brain barrier models: rationale for selection.

  2021cites this paper
• Intranasal Administration for Pain: Oxytocin and Other Polypeptides

  2021cites this paper
• Emerging trends in the delivery of nanoformulated oxytocin across Blood-Brain Barrier.

  2021cites this paper
• Green Nanoparticles: A Hope for Targeted Delivery of Natural Therapeuticals for the Management of Glioblastoma Multiforme (GBM)

  2021cites this paper
• Sweetening Pharmaceutical Radiochemistry by 18F-Fluoroglycosylation: Recent Progress and Future Prospects

  2021cites this paper
• Novel bifunctional hybrid compounds designed to enhance the effects of opioids and antagonize the pronociceptive effects of nonopioid peptides as potent analgesics in a rat model of neuropathic pain

  2020cites this paper
• Peak Filtering, Peak Annotation, and Wildcard Search for Glycoproteomics

  2020cites this paper
• Novel peptide-conjugated nanomedicines for brain targeting: in vivo evidences.

  2020cites this paper
• Impact of non-proteinogenic amino acids in the discovery and development of peptide therapeutics

  2020cites this paper
• Human Serum Albumin-Inspired Glycopeptide-Based Multifunctional Inhibitor of Amyloid-β Toxicity

  2020cites this paper
• Peak Filtering, Peak Annotation, and Wildcard Search for Glycoproteomics.

  2020cites this paper
• Health Implications of A1 and A2 Cow Milk Proteins

  2020cites this paper
• Nanotechnology-based Targeting of Neurodegenerative Disorders: A Promising Tool for Efficient Delivery of Neuromedicines.

  2020cites this paper
• Transcellular brain drug delivery: A review on recent advancements.

  2020cites this paper
• Nanoneuromedicine for management of neurodegenerative disorder

  2019cites this paper
• Peptide-mediated drug delivery across the blood-brain barrier for targeting brain tumors

  2019cites this paper
• Synthesis of oxytocin derivatives lipidated via a carbonate or carbamate linkage as a long-acting therapeutic agent for social impairment-like behaviors.

  2019cites this paper
• Carbohydrates in Vaccine Development.

  2019cites this paper
• A Nanomule Peptide-siRNA Conjugate that Traverses the Intact Blood Brain Barrier and Attenuates Stroke

  2019cites this paper
• Blood Brain Barrier Crossing for Therapeutic and Diagnostic Agents

  2019cites this paper
• Radiosynthesis of an 18 F-fluoroglycosylated aminoferrocene for in-vivo imaging of reactive oxygen species activity by PET.

  2018cites this paper
• Efficient cartridge purification for producing high molar activity [18F]fluoro-glycoconjugates via oxime formation.

  2018cites this paper
• Neuropharmacology in Flux: Molecular Modeling Tools for Understanding Protein Conformational Shifts in Alzheimer’s Disease and Related Disorders

  2018cites this paper
• Reply to the Reviewer’s Comments

  2018cites this paper
• Atorvastatin in PLGA-PEG Nanoparticles derivatized with the HIV-TAT peptide protects neuronal cultures in an Oxygen-Glucose Deprivation (OGD) model

  2018cites this paper
• Herpes Simplex Virus Vectors for Gene Transfer to the Central Nervous System

  2018cites this paper
• Title: Comparative transcriptome profiling of the human and mouse dorsal root ganglia: An RNA-seq-based resource for pain and sensory neuroscience research comparative

  2017cites this paper
• Structure-specific Effects of Lipidated Oxytocin Analogs on Intracellular Calcium Levels, Parental Behavior, Plasma and Cerebrospinal Fluid Oxytocin Concentrations in Mice

  2017cites this paper
• Basic Principles of Formulation for Biotherapeutics: Approaches to Alternative Drug Delivery

  2017cites this paper
• Small molecule piperazinyl-benzimidazole antagonists of the gonadotropin-releasing hormone (GnRH) receptor† †Electronic supplementary information (ESI) available: Detailed experimental procedures and analytical characterisation of all compounds. See DOI: 10.1039/c7md00320j

  2017cites this paper
• Natural Bioactive Compounds: Alternative Approach to the Treatment of Glioblastoma Multiforme

  2017influential citation
• Receptor Targeted Polymeric Nanostructures Capable of Navigating across the Blood-Brain Barrier for Effective Delivery of Neural Therapeutics.

  2017cites this paper
• Role of the sugar moiety on the opioid receptor binding and conformation of a series of enkephalin neoglycopeptides.

  2017cites this paper
• Sequence-Dependent Interfacial Adsorption and Permeation of Dipeptides across Phospholipid Membranes.

  2017cites this paper
• Structure‐specific effects of lipidated oxytocin analogs on intracellular calcium levels, parental behavior, and oxytocin concentrations in the plasma and cerebrospinal fluid in mice

  2017cites this paper
• New gonadotropin-releasing hormone glycolipids with direct antiproliferative activity and gonadotropin-releasing potency.

  2017cites this paper
• Effects of Three Lipidated Oxytocin Analogs on Behavioral Deficits in CD38 Knockout Mice

  2017cites this paper
• Cell-penetrating peptides targeting glioblastomas for nucleic acid delivery in the blood-brain barrier model

  2017cites this paper
• Comparative transcriptome profiling of the human and mouse dorsal root ganglia: An RNA-seq-based resource for pain and sensory neuroscience research

  2017cites this paper
• Glycosylation, an effective synthetic strategy to improve the bioavailability of therapeutic peptides

  2016cites this paper
• Mechanistic and Structural Insights into the Chemical Modulation of Amyloid Aggregation

  2016influential citation
• Enhanced delivery of etoposide across the blood–brain barrier to restrain brain tumor growth using melanotransferrin antibody- and tamoxifen-conjugated solid lipid nanoparticles

  2016cites this paper
• New diketopiperazines as vectors for peptide protection and brain delivery: Synthesis and biological evaluation.

  2016cites this paper
• Neuropeptide systems and new treatments for nicotine addiction

  2016cites this paper
• Early Loss of Blood-Brain Barrier Integrity Precedes NOX2 Elevation in the Prefrontal Cortex of an Animal Model of Psychosis

  2016cites this paper
• Therapeutic Potential of Natural Product-Based Oral Nanomedicines for Stroke Prevention

  2016cites this paper
• Lipo-oxytocin-1, a Novel Oxytocin Analog Conjugated with Two Palmitoyl Groups, Has Long-Lasting Effects on Anxiety-Related Behavior and Social Avoidance in CD157 Knockout Mice

  2015influential citation
• Activation of κ Opioid Receptors in Cutaneous Nerve Endings by Conorphin-1, a Novel Subtype-Selective Conopeptide, Does Not Mediate Peripheral Analgesia.

  2015cites this paper
• Reactivity of Metal-Free and Metal-Associated Amyloid-β with Glycosylated Polyphenols and Their Esterified Derivatives

  2015cites this paper
• Development of Lipid Based Nanoparticulate Drug Delivery Systems and Drug Carrier Complexes for Delivery to Brain

  2015cites this paper
• Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles

  2015cites this paper
• Quorum Sensing Peptides Selectively Penetrate the Blood-Brain Barrier

  2015cites this paper
• BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS.

  2015cites this paper
• Blood-brain transfer and antinociception of linear and cyclic N-methyl-guanidine and thiourea-enkephalins.

  2015cites this paper
• M1 and M2 immune activation in Parkinson's Disease: Foe and ally?

  2015cites this paper
• APOPTOSIS AND INFLAMMATION REGULATION AFTER INJURY TO THE DEVELOPING BRAIN

  2015influential citation
• Increasing the Biological Stability Profile of a New Chemical Entity, UPEI-104, and Potential Use as a Neuroprotectant Against Reperfusion-Injury

  2015cites this paper
• A1 milk and its controversy-a review

  2015cites this paper
• Delivery of Peptide Drugs

  2015cites this paper
• Apoptosis and inflammation regulation after injury to the developing brain

  2015cites this paper
• Stem Cell Therapy for Brain Tumors

  2015cites this paper
• Cell-surface glycan-lectin interactions for biomedical applications

  2015cites this paper
• NMR spectroscopy: a useful tool for drugs development and monitoring biological reactions

  2015cites this paper
• Novel cyclic biphalin analogue with improved antinociceptive properties.

  2014cites this paper
• Current challenges in peptide-based drug discovery

  2014cites this paper
• Development of a Bioavailable μ Opioid Receptor (MOPr) Agonist, δ Opioid Receptor (DOPr) Antagonist Peptide That Evokes Antinociception without Development of Acute Tolerance

  2014cites this paper
• Dynorphins in regulation of immune system functions

  2014cites this paper
• Intranasal Delivery of Neuropeptide-Loaded Nanoparticles and Their Application to Nervous System Therapeutics

  2014cites this paper
• Translation of structure‐activity relationships from cyclic mixed efficacy opioid peptides to linear analogues

  2014cites this paper
• Sweetening Pharmaceutical Radiochemistry by 18F-Fluoroglycosylation: A Short Review

  2014cites this paper
• BDNF–TrkB signaling as a therapeutic target in neuropsychiatric disorders

  2014cites this paper
• Stem cell delivery of therapies for brain disorders

  2014cites this paper
• A Drug Delivery Strategy: Binding Enkephalin to Asialoglycoprotein Receptor by Enzymatic Galactosylation

  2014cites this paper
• Kisspeptin modulates the activity of the stress system and associated behaviours, the body temperature and nociception

  2014cites this paper
• Opioid Peptidomimetics: Leads for the Design of Bioavailable Mixed Efficacy Mu Opioid Receptor (MOR) Agonist/Delta Opioid Receptor (DOR) Antagonist Ligands

  2013cites this paper
• Lipid- and sugar-modified endomorphins: novel targets for the treatment of neuropathic pain

  2013cites this paper
• Targeted Drug Delivery to Treat Pain and Cerebral Hypoxia

  2013cites this paper
• Peptide Modifications to Increase Metabolic Stability and Activity

  2013cites this paper
• Altered serum stress neuropeptide levels in critically ill individuals and associations with lymphocyte populations.

  2013cites this paper